Charakteristika predkladané
Characteristics of the submitte

Tlačivo VTČ slúži na predkladanie výstupov tvorivej činnosti podľa metodiky hodno
form is used to submit the research/artistic/other outputs according to the evalua
Standards Evaluation).

ID konania/ID of the procedure: [1]
Kód VTČ/Code of the research/artistic/other output (RAOO):[1]

OCA1. Priezvisko hodnotenej osoby / Surname awarded to the assessed person [2]	
OCA2. Meno hodnotenej osoby / Name awarded to the assessed person [2]	
OCA3. Tituly hodnotenej osoby / Degrees awarded to the assessed person [2]	
OCA4. Hyperlink na záznam osoby v Registri zamestnancov vysokých škôl / Hyperlink to the entry of the person in the Register of university staff [3]	
OCA5. Oblasť posudzovania / Area of assessment [4]	
OCA6. Kategória výstupu tvorivej činnosti / Category of the research/ artistic/other output *Výber zo 6 možností (pozri Vysvetlivky k položke OCA6) / Choice from 6 options (see Explanations for OCA6).*	
OCA7. Rok vydania výstupu tvorivej činnosti / Year of publication of the research/artistic/other output	
OCA8. ID záznamu v CREPČ alebo CREUČ *(ak je)* / ID of the record in the Central Registry of Publication Activity (CRPA) or the Central Registry of Artistic Activity (CRAA) [5]	
OCA9. Hyperlink na záznam v CREPČ alebo CREUČ / Hyperlink to the record in CRPA or CRAA [6]	
Characteristics of the output that is not registered in CRPA or CRAA	OCA10. Hyperlink na záznam v inom verejne prístupnom registri, katalógu výstupov tvorivých činností / Hyperlink to the record in another publicly accessible register, catalogue of research/ artistic/other outputs [7]
	OCA11. Charakteristika výstupu vo formáte bibliografického záznamu CREPČ alebo CREUČ, ak výstup nie je vo verejne prístupnom registri alebo katalógu výstupov / Characteristics of the output in the format of the CRPA or the CRAA bibliographic record, if the output is not available in a publicly accessible register or catalogue of outputs

Charakteristika výstupu, ktorý nie je registrovaný v CREPČ alebo CREUČ / C

OCA12. Typ výstupu (ak nie je výstup registrovaný v CREPČ alebo CREUČ) / Type of the output (if the output is not registered in CRPA or CRAA)
Výber zo 67 možností (pozri Vysvetlivky k položke OCA12) / Choice from 67 options (see Explanations for OCA12).

OCA13. Hyperlink na stránku, na ktorej je výstup sprístupnený (úplný text, iná dokumentácia a podobne) / Hyperlink to the webpage where the output is available (full text, other documentation, etc.)

OCA14. Charakteristika autorského vkladu / Characteristics of the author's contribution

OCA15. Anotácia výstupu s kontextovými informáciami týkajúcimi sa opisu tvorivého procesu a obsahu tvorivej činnosti a pod. / Annotation of the output with contextual information concerning the description of creative process and the content of the research/artistic/other activity, etc. [8]
Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in Slovak
Rozsah do 200 slov v anglickom jazyku / Range up to 200 words in English

OCA16. Anotácia výstupu v anglickom jazyku / Annotation of the output in English [9]
Rozsah do 200 slov / Range up to 200 words

OCA17. Zoznam najviac 5 najvýznamnejších ohlasov na výstup / List of maximum 5 most significant citations corresponding to the output
Rozsah do 200 slov / Range up to 200 words

OCA18. Charakteristika dopadu výstupu na spoločensko-hospodársku prax / Characteristics of the output's impact on socio-economic practice
Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in Slovak
Rozsah do 200 slov v anglickom jazyku / Range up to 200 words in English

OCA19. Charakteristika dopadu výstupu a súvisiacich aktivít na vzdelávací proces / Characteristics of the output and related activities' impact on the educational process
Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in Slovak
Rozsah do 200 slov v anglickom jazyku / Range up to 200 words in English

ho výstupu tvorivej činnosti /
d research/ artistic/other output

tenia tvorivých činností (časť V. Metodiky na vyhodnocovanie štandardov) / The
tion methodology of research/artistic/other activities (part V. The Methodology for

11.12.2021

KMEC
Ján
prof. MUDr. PhD., MPH, FESC
https://www.portalvs.sk/regzam/detail/6789
Urgentná zdravotná starostlivosť,1. stupeň/Emergency health care, 1. degree
vedecký výstup / science output
2019
163724
https://app.crepc.sk/?fn=detailBiblioForm&sid=8DB42373D07F62A0DAAF45CC59
https://pubmed.ncbi.nlm.nih.gov/31132222/
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world / Kapelios, Chris J. [Autor, 0.532%] ; Lainscak, Matja [Autor, 0.162%] ; Savarese, Gianluigi [Autor, 0.162%] ; Laroche, Cecile [Autor, 0.162%] ; Seferovic, Petar [Autor, 0.162%] ; Murín, Ján [Autor, UKOLF1IK, 0.162%] ; Goncalvesová, Eva [Autor, UKOLFKK, 0.162%] ; Kmec, Ján [Autor, PUPFZUZS, 0.162%]. – text. – [angličtina]. – [OV 180]. – [článok]. – SIGN-UKO LF 1IK/19. – SIGN-PU FZ-20 231/19. – WOS CC ; SCOPUS ; CCC In: European Journal of Heart Failure [textový dokument (print)] [elektronický dokument] : journal of the Working Group on Heart Failure of the European Society of Cardiology. – Chichester, WestSussex (Veľká Británia) : John Wiley & Sons. – ISSN 1388-9842. – ISSN (online) 1879-0844. – Roč. 21, č. 11 (2019), s. 1383-1397 [tlačená forma] [online] . – IF: 11,627 ; SNIP: 3,53 ; SJR: 5,556 ; CiteScore: 22

článok/ article
0.162%
Posúdenie podielu pacientov so srdcovým zlyhaním a zníženou ejekčnou frakciou (HFrEF), ktorí sú spôsobilí na liečbu sakubitrilom/valsartanom (LCZ696), na základe označenia Európskej agentúry pre lieky/Správy pre potraviny a liečivá (EMA/FDA), štúdie PARADIGM-HF a usmernenia HSR z roku 2016 a súvislosť medzi oprávnenosťou a výsledkami./Assessment of the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for treatment with sacubitrile / valsartan (LCZ696), based on the designation of the European Medicines Agency / Food and Drug Administration (EMA / FDA), the PARADIGM-HF study and the 2016 ESC guidelines and the link between eligibility and results.
To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug Administration (EMA/FDA) label, the PARADIGM-HF trial and the 2016 ESC guidelines, and the association between eligibility and outcomes.

2019 01 (SCOPUS:2-s2.0-85069936793; Web of Science Core Collection:WOS:000477347300001) 175264: Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? / Ambrosy, Andrew P. [Autor] ; Fudim, Marat [Autor] ; Chioncel, Ovidiu [Autor]. – DOI 10.1002/ejhf.1555. – WOS CC ; SCOPUS In: European Journal of Heart Failure [textový dokument (print)] [elektronický dokument] : journal of the Working Group on Heart Failure of the European Society of Cardiology. – Chichester, WestSussex (Veľká Británia) : John Wiley & Sons. – ISSN 1388-9842. – ISSN (online) 1879-0844. – Roč. 21, č. 11 (2019), 1398-1401 [tlačená forma] [online]

2020 01 (SCOPUS:2-s2.0-85083664321; Web of Science Core Collection:WOS:000527767800001) 242859: Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system / Gatti, Milo [Autor, 20%] ; Antonazzo, Ippazio Cosimo [Autor, 20%] ; Diemberger, Igor [Autor, 20%] ; De Ponti, Fabrizio [Autor, 20%] ; Raschi, Emanuel [Autor, 20%]. – DOI 10.1177/2047487320915663. – WOS CC ; SCOPUS In: European Journal of Preventive Cardiology [textový dokument (print)] [elektronický dokument] . – Veľká Británia : SAGE Publications, Londýn (Veľká Británia) : European Society of Cardiology. – ISSN 2047-4873. – ISSN (online) 2047-4881. – 2020, [online] [tlačená forma] 2020 01 (Current Content Connect:CCC:000552896600002; SCOPUS:2-s2.0-85077016447; Web of Science Core Collection:WOS:000552896600002) 242860: The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016 / Chen, Xiaojing [Autor, 33.333%] ; Schaufelberger, Maria [Autor, 33.334%] ; Fu, Michael [Autor, 33.333%]. – DOI 10.2459/JCM.0000000000000889. – WOS CC ; SCOPUS ; CCC In: Journal of cardiovascular medicine [textový dokument (print)] [elektronický dokument] . – Hagerstown (USA) : Wolters Kluwer. Lippincott Williams & Wilkins. – ISSN 1558-2027. – ISSN (online) 1558-2035. – Roč. 21, č. 1 (2020), 6-12 [tlačená forma] [online]

2020 01 (SCOPUS:2-s2.0-85083105596; Current Content Connect:CCC:000536512400024; Web of Science Core Collection:WOS:000522551300001) 203661: Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan / Mazzetti, Simone [Autor] ; Scifo, Chiara [Autor] ; Abete, Raffaele [Autor] ; Margonato, Davide [Autor] ; Chioffi, Margherita M. [Autor] ; Rossi, Jessica [Autor] ; Pisani, Matteo [Autor] ; Passafaro, Giovanni [Autor] ; Grillo, Massimiliano [Autor] ; Poggio, Daniele [Autor] ; Mortara, Andrea [Autor]. – DOI

Spomedzi ambulantných pacientov s HFrEF v registri ESC-EORP-HFA HF-LT spĺňalo kritériá označovania 84%, zatiaľ čo iba 12% a 28% spĺňalo kritériá PARADIGM-HF a smerné kritériá pre LCZ696, ak si to vyžaduje ≥ 20 mg, respektíve ≥ 10 mg enalaprilu . Registrovaní pacienti spôsobilí pre LCZ696 mali väčšiu hospitalizáciu so srdcovým zlyhaním, ale nižšiu úmrtnosť ako skupina PARADIGM-HF enalapril./Among outpatients with HFrEF in the ESC-EORP-HFA registry, HF-LT met 84% of the labeling criteria, while only 12% and 28% met the PARADIGM-HF and LCZ696 guideline criteria, if required ≥ 20 mg and ≥ 20 mg, respectively. 10 mg enalapril. Registered patients eligible for LCZ696 had higher hospitalizations with heart failure but lower mortality than the PARADIGM-HF enalapril group.

Vyber ambulantných pacientov s HFrEF,ktorí boli v registri ESC-EORP-HFA Long-Term Heart Failure (HF-LT).Použili sa kritériá pre LCZ696 na základe štítku EMA/FDA, usmernení PARADIGM-HF a ESC. Z 5443 pacientov malo 2197 a 2373 úplné informácie o posúdení vhodnosti pre skúšanie a usmernenie a 84%, 12% a 12% splnilo kritériá EMA/FDA, PARADIGM-HF a kritériá pre poradenstvo./Selection of outpatients with HFrEF who were on the ESC-EORP-HFA Long-Term Heart Failure (HF-LT) registry. The criteria for LCZ696 based on the EMA / FDA label, PARADIGM-HF and ESC guidelines were used. Of the 5443 patients, 2197 and 2373 had complete information on assessment suitability and guidance, and 84%, 12%, and 12% met the EMA / FDA, PARADIGM-HF, and counseling criteria.